SCNX
Scienture Holdings, Inc.
$0.3520
-2.22%
$14.9M
No data for this timeframe.
Vol
Market Cap$14.9M
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$309.3K
Inst. Activity2 buys / 0 sells
Reddit Sentiment67° Warm
SEC Reports5
Recent Activity
May 29, 2026
SEC
Scienture Holdings CFO Eric Sherb resigned effective May 26, 2026 for personal reasons, with no dispute or disagreement.
8-K — Impact 4/10
May 22, 2026
SEC
Scienture Holdings reported Q1 2026 revenue of ~$56K (up 449% YoY from ~$10K) and gross margin expansion to 95.6%, drive
8-K — Impact 5/10
May 18, 2026
SEC
Scienture reported Q1 2026 revenue of $56K (up 449% YoY from $10K) and EPS of -$0.08, beating consensus of -$0.23 by 65.
PRESS-RELEASE — Impact 6/10
Feb 20, 2026
Insider
Shankar Hariharan sold 500,000 shares
Co-CEO & Chairman @ $0.00 ($0.00)
Feb 20, 2026
Insider
Narasimhan Mani sold 500,000 shares
President & Co-CEO @ $0.00 ($0.00)
Oct 1, 2025
Insider
Shankar Hariharan sold 300,000 shares
Co-CEO & Chairman @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — DOUBLED
606,151 shares ($309.1K)
Inst.
BANK OF AMERICA CORP — DOUBLED
287 shares ($146.00)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$1.50 (Feb 2026)
Current $0.3660
Low $1.50
Median $1.50
High $1.50
1 analysts
$1.50
$1.50
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 24, 2026 | Maxim Group | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 | $-0.23 — $-0.23 | 1 | |
| Next Q | $-0.18 | $-0.18 — $-0.18 | 1 | |
| Current FY | $-0.72 | $-0.72 — $-0.72 | 1 | |
| Next FY | $-0.21 | $-0.21 — $-0.21 | 71% YoY | 1 |
Latest Reports
NEUTRAL
8-K
4/10
Scienture Holdings CFO Eric Sherb resigned effective May 26, 2026 for personal reasons, with no dispute or disagreement.
May 29, 2026
NEUTRAL
8-K
5/10
Scienture Holdings reported Q1 2026 revenue of ~$56K (up 449% YoY from ~$10K) and gross margin expansion to 95.6%, drive
May 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $309.1K | DOUBLED |
| BANK OF AMERICA CORP | $146.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 20, 2026 | Shankar Hariharan | A | $0.00 |
| Feb 20, 2026 | Narasimhan Mani | A | $0.00 |
| Oct 1, 2025 | Shankar Hariharan | A | $0.00 |
| Oct 1, 2025 | Narasimhan Mani | A | $0.00 |
| Apr 14, 2025 | Narasimhan Mani | A | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
2 institutional holders with $309.3K total value (606,438 shares) as of 2025-Q4. Top holders: VANGUARD, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 606,151 | $309.1K | 100.0% | DOUBLED +286.0% |
| 2 | BANK OF AMERICA CORP /DE/ | 287 | $146.00 | 0.0% | DOUBLED +176.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 157,018 | 606,151 | +286.0% | $309.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 104 | 287 | +176.0% | $146.00 | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 14,566 | 157,018 | +978.0% | $133.5K | 2025-Q3 |
| UBS Group AG | NEW | — | 114,351 | — | $97.2K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 76 | 104 | +36.8% | $89.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 30 | 76 | +153.3% | $79.00 | 2025-Q2 |
| UBS Group AG | EXIT | 8,010 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 3,532 | 8,010 | +126.8% | $11.5K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 20,100 | 0 | -100.0% | $0.00 | 2025-Q1 |
2 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | Shankar Hariharan | Co-CEO & Chairman | A | 500,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Narasimhan Mani | President & Co-CEO | A | 500,000 | $0.00 | $0.00 |
| Oct 1, 2025 | Shankar Hariharan | Co-CEO & Chairman | A | 300,000 | $0.00 | $0.00 |
| Oct 1, 2025 | Narasimhan Mani | President & Co-CEO | A | 300,000 | $0.00 | $0.00 |
| Apr 14, 2025 | Narasimhan Mani | President & Co-CEO | A | 750,000 | $0.00 | $0.00 |
| Apr 14, 2025 | Shankar Hariharan | Co-CEO & Chairman | A | 750,000 | $0.00 | $0.00 |
| Mar 10, 2025 | Shankar Hariharan | Co-CEO & Chairman | J | 30,000 | $0.00 | $0.00 |
| Mar 10, 2025 | Narasimhan Mani | President & Co-CEO | J | 20,000 | $0.00 | $0.00 |
| Sep 19, 2024 | Shankar Hariharan | Co-CEO & Chairman | C | 1,916,816 | $0.00 | $0.00 |
| Sep 19, 2024 | Shankar Hariharan | Co-CEO & Chairman | C | 1,916,816 | $0.00 | $0.00 |
| Sep 19, 2024 | Narasimhan Mani | President & Co-CEO | C | 1,357,538 | $0.00 | $0.00 |
| Sep 19, 2024 | Narasimhan Mani | President & Co-CEO | C | 1,357,538 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.8/10.
NEUTRAL
8-K
4/10
Scienture Holdings CFO Eric Sherb resigned effective May 26, 2026 for personal reasons, with no disp
May 29, 2026
NEUTRAL
8-K
5/10
Scienture Holdings reported Q1 2026 revenue of ~$56K (up 449% YoY from ~$10K) and gross margin expan
May 22, 2026
BULLISH
PRESS-RELEASE
6/10
Scienture reported Q1 2026 revenue of $56K (up 449% YoY from $10K) and EPS of -$0.08, beating consen
May 18, 2026
NEUTRAL
8-K
2/10
Scienture Holdings posted a revised investor presentation to its website on May 5, 2026, for use in
May 5, 2026
BEARISH
10-K/A
7/10
Scienture Holdings filed Amendment No. 1 to its 2025 10-K to correct immaterial errors in Item 7 (MD
Apr 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$1.50 mean target (Feb 2026)
$1.50 Low
$1.50 High
| Metric | Value |
|---|---|
| Current Price | $0.3660 |
| Target Low | $1.50 |
| Target Mean | $1.50 |
| Target Median | $1.50 |
| Target High | $1.50 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.23 | $-0.23 | $-0.23 | — | — | — | $0.0B | — | 1 |
| Next Q 2026-09-30 |
$-0.18 | $-0.18 | $-0.18 | — | — | — | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-0.72 | $-0.72 | $-0.72 | — | — | — | $0.0B | 1074.0% | 1 |
| Next FY 2027-12-31 |
$-0.21 | $-0.21 | $-0.21 | 70.8% | — | — | $0.0B | 239.8% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.230 | |
| 7d ago | $0.000 | -0.230 |
| 30d ago | $0.000 | -0.230 |
| 60d ago | $0.000 | -0.230 |
| 90d ago | $0.000 | -0.230 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 24, 2026 | Maxim Group | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2024 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2024 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 16, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
$COCH is the future of implants and hearing
▲ 2
💬 9
⚡ 0.0
Jun 9, 2026
other
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
<p align="center"><b>Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institution
Jun 2, 2026
other
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
<p align="center"><b>U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually</b></p>
May 18, 2026
earnings
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
<p align="justify"><b>COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.</b><b> (NASDAQ: SCNX) (“Scienture”), </b>a holding comp
May 13, 2026
earnings_calendar
SCNX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
SCNX Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
other
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
<p align="center"><i>Proceeds support commercialization of Arbli</i><sup><i>™</i></sup><i>, the first FDA-approved ready-to-use oral suspension for hy
May 6, 2026
other
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
<p align="center"><b>U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for AR
Apr 15, 2026
other
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
<p align="justify"><b>COMMACK, NY, April 15, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”)</b> a holding company fo
Apr 6, 2026
other
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
<p align="justify"><b>COMMACK, NY, April 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”)</b> a holding company fo
Mar 30, 2026
earnings
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
<p align="center"><b>Reports Significant Revenue Growth and Gross Margin Expansion in 2025</b></p>
Mar 24, 2026
earnings_calendar
SCNX Q4 2025 Earnings Scheduled — 2026-03-24
Mar 11, 2026
other
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
<p align="center"><b>Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EM
Mar 13, 2025
FDA
ARBLI
Mar 13, 2025
FDA
ARBLI
Apr 19, 2024
FDA
REZENOPY
Original Approval — Type 5 - New Formulation or New Manufacturer — NALOXONE HCL — SPRAY — NASAL